Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clovis Oncology Seeks $149.5 Million IPO

This article was originally published in The Pink Sheet Daily

Executive Summary

The Colorado cancer drug maker is seeking financing through the public capital markets.
Advertisement

Related Content

Third Rock Ventures Pumps $38 Million Into New Firm Focused On Genetic Heart Disease
Start-Up Quarterly Statistics, Q4 2011
Biopharma Out-licensing: 2012’s “In” Thing?
Biopharma Out-licensing: 2012’s “In” Thing?
Clovis And Clavis' Gemcitabine Derivative Partnership Goes From Regional To Worldwide
Use Of Protein Biomarkers Punctuates Clovis' Fast-Paced Clinical Trials Strategy
Biotech Backers Learn To Live With Exit-By-Earn-Out
Biotech Backers Learn To Live With Exit-By-Earn-Out
Clovis Taps Into Rich "A" Round, Grabs Licensing Rights to Improved Gemcitabine
Former Pharmion Principals Start Over In Oncology With Clovis

Topics

Advertisement
UsernamePublicRestriction

Register

PS072412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel